TP53 and epilepsy: Given that many therapeutic agents targeting Mdm2 or Mdm2-p53 signaling are clinically available or being developed, a better understanding of Mdm2 would benefit future therapeutic development for seizures, epilepsies, and other neurological conditions associated with excessive neural activity.